JAFA runs a regular educational online symposia series on Critical Issues in Juvenile Arthritis, to help parents, older children and young people navigate the health system and keep up with new developments in the management of juvenile arthritis.
Leading paediatric rheumatologists, nurses, physios and other professionals share their knowledge and expertise on advances in treatment, services, health policy and research. Each symposium features a popular 30 minute Q&A with an Expert Panel of speakers.
See videos of previous symposia and information about the upcoming symposia below.
JAFA’s latest symposium explores the complex maze of benefits that are potentially available to help meet the increased need for social and health related services in families who have a child with juvenile arthritis with serious physical or other challenges.
This JAFA online symposium shines a light on the link between chronic childhood conditions and mental ill health. Expert speakers outline what is known about the nature and extent of the problem and focus on emerging approaches for reducing the impact of these diseases
on the child and family.
This symposium focusses on the evidence from current and emerging Australian and International research. Top Australian paediatric rheumatology and academic researchers provided updates on
their work including clinical outcomes for Juvenile Arthritis; living guidelines for JIA; health service utilisation and how much exercise is too much or not enough.
In this symposium the pros and cons of current and emerging medications for children with juvenile arthritis. Australian paediatric rheumatologists explore the A to Z of available and emerging medicines for Juvenile Arthritis and the role of the Pharmaceutical Benefits Scheme (PBS).
Australian paediatric rheumatologists discuss services and expectations for young people entering adulthood. The symposium also provides an update on COVID vaccines, treatment and outcomes.
Four of Australia’s leading paediatric rheumatologists speak on topical issues in treatment research, and current thinking about the impact of COVID-19 on children with Juvenile Arthritis.